10x Genomics Reports Q3 Revenue of $150.7 Million, Raises 2026 Guidance
Third-quarter revenue was $150.7 million versus a $148.0 million FactSet consensus estimate. The company reported a $0.15-per-share loss, narrowed operating losses to $16.1 million from $32.2 million a year earlier, and improved gross margin to 75% from 67%.
10x Genomics reported third-quarter 2026 revenue of $150.7 million, exceeding the FactSet consensus estimate of $148.0 million. The company also reported a net loss of $0.15 per share, which was better than the anticipated $0.27 loss per share. Operating losses narrowed to $16.1 million from $32.2 million in the prior-year period, while gross margins improved to 75% from 67%. Following these results, the company raised its full-year 2026 revenue guidance to a range of $625 million to $635 million, up from its previous forecast of $610 million to $630 million.
Management noted that, excluding non-recurring revenue from patent litigation agreements, the company expects 4%—6% growth compared to 2025.